HistoSonics Advances Histotripsy Applications with FDA Submission for Kidney Tumors
HistoSonics has announced a move to advance its histotripsy technology by submitting a proposal to the FDA for the treatment of kidney tumors. This step represents the company’s efforts to expand the applications of its innovative medical technology.
MINNEAPOLIS–(BUSINESS WIRE)– #HistoSonics–HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors